Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries

BACKGROUND & AIMS: Observational studies have linked lipid-lowering drug targets pro-protein convertase subtilisin/kexin 9 (PCSK9) and HMG-CoA reductase (HMGCR) with adverse liver outcomes; however, liver disease incidence varies across diverse populations, and the long-term hepatic impact of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosoff, Daniel B., Bell, Andrew S., Wagner, Josephin, Mavromatis, Lucas A., Hamandi, Ali, Park, Lauren, Jung, Jeesun, Lohoff, Falk W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665960/
https://www.ncbi.nlm.nih.gov/pubmed/37703945
http://dx.doi.org/10.1016/j.jcmgh.2023.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665960/
https://www.ncbi.nlm.nih.gov/pubmed/37703945
http://dx.doi.org/10.1016/j.jcmgh.2023.09.001

Ejemplares similares